1116 related articles for article (PubMed ID: 27001573)
1. [18F]Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET)/Computed Tomography (CT) in Suspected Recurrent Breast Cancer: A Prospective Comparative Study of Dual-Time-Point FDG-PET/CT, Contrast-Enhanced CT, and Bone Scintigraphy.
Hildebrandt MG; Gerke O; Baun C; Falch K; Hansen JA; Farahani ZA; Petersen H; Larsen LB; Duvnjak S; Buskevica I; Bektas S; Søe K; Jylling AM; Ewertz M; Alavi A; Høilund-Carlsen PF
J Clin Oncol; 2016 Jun; 34(16):1889-97. PubMed ID: 27001573
[TBL] [Abstract][Full Text] [Related]
2. Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma.
Rayamajhi S; Balachandran A; Katz M; Reddy A; Rohren E; Bhosale P
Abdom Radiol (NY); 2018 Feb; 43(2):505-513. PubMed ID: 28900703
[TBL] [Abstract][Full Text] [Related]
3. FDG-PET/contrast-enhanced CT as a post-treatment tool in head and neck squamous cell carcinoma: comparison with FDG-PET/non-contrast-enhanced CT and contrast-enhanced CT.
Suenaga Y; Kitajima K; Ishihara T; Sasaki R; Otsuki N; Nibu K; Minamikawa T; Kiyota N; Sugimura K
Eur Radiol; 2016 Apr; 26(4):1018-30. PubMed ID: 26188656
[TBL] [Abstract][Full Text] [Related]
4. Whole-body
Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels.
Bhosale P; Peungjesada S; Wei W; Levenback CF; Schmeler K; Rohren E; Macapinlac HA; Iyer RB
Int J Gynecol Cancer; 2010 Aug; 20(6):936-44. PubMed ID: 20683399
[TBL] [Abstract][Full Text] [Related]
6. Three-Dimensional Image Fusion of
Yu Y; Zhang WB; Liu XJ; Guo CB; Yu GY; Peng X
J Oral Maxillofac Surg; 2017 Jun; 75(6):1301.e1-1301.e15. PubMed ID: 28320612
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis of bone metastases in breast cancer: Lesion-based sensitivity of dual-time-point FDG-PET/CT compared to low-dose CT and bone scintigraphy.
Hansen JA; Naghavi-Behzad M; Gerke O; Baun C; Falch K; Duvnjak S; Alavi A; Høilund-Carlsen PF; Hildebrandt MG
PLoS One; 2021; 16(11):e0260066. PubMed ID: 34793550
[TBL] [Abstract][Full Text] [Related]
8. Comparison of (18) F-FDG-PET-CT and Bone Scintigraphy for Evaluation of Osseous Metastases in Newly Diagnosed and Recurrent Osteosarcoma.
Hurley C; McCarville MB; Shulkin BL; Mao S; Wu J; Navid F; Daw NC; Pappo AS; Bishop MW
Pediatr Blood Cancer; 2016 Aug; 63(8):1381-6. PubMed ID: 27082077
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic value of integrated ¹⁸F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in recurrent epithelial ovarian cancer: accuracy of patient selection for secondary cytoreduction in 134 patients.
Lee YJ; Kim YM; Jung PS; Lee JJ; Kim JK; Kim YT; Nam JH
J Gynecol Oncol; 2018 May; 29(3):e36. PubMed ID: 29400023
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic efficacy of 18F-FDG-PET or PET/CT in breast cancer with suspected recurrence: a systematic review and meta-analysis.
Xiao Y; Wang L; Jiang X; She W; He L; Hu G
Nucl Med Commun; 2016 Nov; 37(11):1180-8. PubMed ID: 27428888
[TBL] [Abstract][Full Text] [Related]
11. Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study.
Zattoni F; Incerti E; Colicchia M; Castellucci P; Panareo S; Picchio M; Fallanca F; Briganti A; Moschini M; Gallina A; Karnes JR; Lowe V; Fanti S; Schiavina R; Rambaldi I; Ficarra V; Evangelista L
Abdom Radiol (NY); 2018 Sep; 43(9):2391-2399. PubMed ID: 29302738
[TBL] [Abstract][Full Text] [Related]
12. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
14. Serum carcinoembryonic antigen measurement, abdominal contrast-enhanced computed tomography, and fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in the detection of colorectal cancer recurrence: a correlative study.
Ozkan E; Soydal C; Araz M; Aras G
Nucl Med Commun; 2012 Sep; 33(9):990-4. PubMed ID: 22842225
[TBL] [Abstract][Full Text] [Related]
15. (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma.
Al-Ibraheem A; Buck AK; Benz MR; Rudert M; Beer AJ; Mansour A; Pomykala KL; Haller B; Juenger H; Scheidhauer K; Schwaiger M; Herrmann K
Cancer; 2013 Mar; 119(6):1227-34. PubMed ID: 23233156
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
Qiu ZL; Xue YL; Song HJ; Luo QY
Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
[TBL] [Abstract][Full Text] [Related]
17. Added value of pretreatment (18)F-FDG PET/CT for staging of advanced gastric cancer: Comparison with contrast-enhanced MDCT.
Kawanaka Y; Kitajima K; Fukushima K; Mouri M; Doi H; Oshima T; Niwa H; Kaibe N; Sasako M; Tomita T; Miwa H; Hirota S
Eur J Radiol; 2016 May; 85(5):989-95. PubMed ID: 27130061
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Bone Lesions with
van Es SC; Velleman T; Elias SG; Bensch F; Brouwers AH; Glaudemans AWJM; Kwee TC; Iersel MW; Maduro JH; Oosting SF; de Vries EGE; Schröder CP
J Nucl Med; 2021 Feb; 62(2):177-183. PubMed ID: 32817140
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic accuracy of ¹⁸F-FDG PET/CT for detection of suspected recurrence in patients with oesophageal carcinoma.
Sharma P; Jain S; Karunanithi S; Pal S; Julka PK; Thulkar S; Malhotra A; Bal C; Kumar R
Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1084-92. PubMed ID: 24435775
[TBL] [Abstract][Full Text] [Related]
20. The diagnostic performance of CT versus FDG PET-CT for the detection of recurrent pancreatic cancer: a systematic review and meta-analysis.
Daamen LA; Groot VP; Goense L; Wessels FJ; Borel Rinkes IH; Intven MPW; van Santvoort HC; Molenaar IQ
Eur J Radiol; 2018 Sep; 106():128-136. PubMed ID: 30150034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
